ClinicalTrials.gg
RecruitingNCT07102030SLEsubgroupsUpdated Aug 3, 2025

Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment

An observational study in Systemic Lupus Erythematosus, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Region Stockholm · Observational

How we know

From the registry’s dates

  • Started Feb 2015; still recruiting 11 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
900
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lupus Erythematosus, Systemic with a site in Sweden — 6 open to participants now, 10 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · Sweden.

Started
2015
the only one that year
Observational
6 of 19
3 open now
Registered
18th of 19
by date

Among the 19 studies in Lupus Erythematosus, Systemic with a site in Sweden, this one is the only one that started in 2015, is one of 6 observational ones, and was the 18th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

6 of the 19 studies in Lupus Erythematosus, Systemic with a site in Sweden are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lupus Erythematosus, Systemic with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this observational study is to investigate different phenotypes among patients with SLE and to compare with matched general population controls. The main questions we aim to answer are:

A To investigate if subgroups of patients with systemic lupus erythematosus (SLE) defined by autoantibodies, genetic predisposition or biomarkers, rather than the present diagnostic entities account for the high risk of premature vascular disease.

B To perform in depth studies of selected patient groups to shed light on the autoimmune mechanisms behind antiphospholipid (aPL) antibodies and nephritis and their association to vascular disease in SLE and APS Participants will be investigated in person by a nurse and a rheumatologist. Data on previous and present disease characteristics, anthropometric measurements and health related quality of life (according to selfreported questionnaires) will be entered into a data base. Blood samples (plasma serum and DNA), urine and saliva is stored in a corresponding biobank.

Researchers will compare identified subgroups of SLE patients to each other and to matched population controls.

Read the detailed description

The clinical base for this application is a series of cross-sectional studies, performed every 10 years, including all consenting SLE patients at Rheumatology Karolinska. The first studies were initiated 1995-99, with second follow-up 2004-14. Since 2015, a third follow-up of prevalent and new cases is ongoing (presently comprising 400 patients, inclusions have been temporarily slowed by the Covid-19 pandemic). Very detailed clinical characterization, lifestyle questionnaires, together with results from carotid ultrasound and bone mineral density measures have been tabulated. General disease activity as well as features of lupus nephritis, and detailed autoantibody profiles are recorded at inclusion. Samples (plasma, serum, DNA, urine and saliva) are stored. We have a common database for the three cross-sectional studies. The total number of well-characterized SLE patients in these studies is today 867 SLE patients and >250 APS patients.

Population based controls identified in the national population registry (NPR), individually matched for age, sex, and residency have been investigated in person according to the same structured protocol (n=320). New controls will be included to match the "2015+ study".

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

SLE patients as described above who are cared for at karolinska University Hospital, Danderyds Hospital or Center forRheumathology (CFR) in Stockholm and matched general population controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

SLE according to criteria (ACR82 or SLICC 2012) and consenting to participate

Exclusion criteria

Exclusion Criteria:

Not possible to read and understand patient information due to language barriers or psychological/psychiatric disorders Not consenting

-

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
900 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • SLE patients

    Patients fulfilling ACR 1982 or SLICC 2012 criteria for SLE. No interventions

  • Controls

    General population controls matched from the National Patient Registries for age, gender and area of living

06

What researchers measure

Primary outcomes

  1. Autoantibody defined subgroups

    Subgroups will be defined based on presence of autoantibodies

    Time frame: 2024- 2027

  2. Cardiovascular events

    Cardiovascular events will be collected during follow up in National Patient Registries

    Time frame: 2024-2027

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Clinical and autoantibody data collected at inclusion

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: July 15 2025 until July 15 2027

Access criteria: Selected data will be shared with Christian Lood, University of Washington USA, using Managed File Transfer at Karolinska Institutet.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2015 (actual). Primary completion is estimated for Dec 2029, 178 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 3, 2025
StartActual
Feb 15, 2015
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2032
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07102030
Lead sponsor
Region Stockholm
Collaborators
Karolinska Institutet, National Institutes of Health (NIH), The Swedish Research Council, Reumatikerförbundet
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Feb 15, 2015
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Aug 3, 2025

Study contacts

Elisabet Svenungsson, MD, PhD
Contact
elisabet.svenungsson@ki.se
+46760069142
Iva Gunnarsson, MD, PhD
Contact
Iva.gunnarsson@regionstockholm.se

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion